-
-
-
-
-
-
-
Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential
-
-
-
-
-
-
-
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
-
-
-
-
-
-
-
Pre-Open Movers 02/14: (FOSL) (IPCC) (CMG) Higher; (TTPH) (GLMD) (PIRS) Lower (more...)
-
-
-
-
-
-
-
Pre-Open Stock Movers 01/05: (PIRS) (CTIC) (CEB) Higher; (AEZS) (KSS) (M) Lower (more...)
-
-
-
-
-
1,154,869 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

